Developing antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology.
Location: United States
Total raised: $157M
Investors 2
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| 01.02.2026 | Avego | avego.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.01.2026 | Series B | $107M | Johnson &a... |
| 22.03.2023 | Series A | $50M | Mubadala C... |
Mentions in press and media 8
| Date | Title | Description |
| 11.01.2026 | EpiBiologics Secures $107M Series B, Propelling Precision Protein Degradation for Cancer and Immunity | EpiBiologics closed a $107 million Series B. This investment accelerates its EpiTAC platform. The platform develops tissue-selective extracellular protein degraders. These target disease-driving membrane and soluble proteins. Lead candidate... |
| 10.01.2026 | EpiBiologics: $107 Million Series B Raised To Advance Tissue-Selective EGFR Degrader And Bispecific Antibody Pipeline | EpiBiologics announced it has closed a $107 million Series B financing to advance a pipeline of bispecific antibodies designed to selectively degrade extracellular protein targets in oncology and immunology. The round was co-led by GV and J... |
| 08.01.2026 | EpiBiologics Closes $107M Series B Funding | EpiBiologics, a San Mateo, CA-based company which specializes in tissue-selective extracellular protein degradation, raised $107M in Series B funding. The round was co-led by GV (Google Ventures) and Johnson & Johnson, through its corpo... |
| 08.01.2026 | Red Hat Acquires Chatterbox | Red Hat, a Raleigh, N.C.-based provider of open source solutions, acquired Chatterbox Labs, a developer of model-agnostic AI safety and generative AI (gen AI) guardrails. The amount of the deal was not disclosed. This acquisition adds criti... |
| 22.03.2023 | EpiBiologics Raises $50M in Series A Financing | EpiBiologics, a San Mateo, CA-based biotechnology company building a next-generation antibody-based protein degradation platform, raised $50M in Series A funding. The round was led by Mubadala Capital and Polaris Partners, with participatio... |
| 22.03.2023 | EpiBiologics Launches with $50M Series A Financing | SAN MATEO, CA, EpiBiologics launches with $50 million in Series A funding led by Mubadala Capital and Polaris Partners. >> Click here for more funding data on EpiBiologics >> To export EpiBiologics funding data to PDF and Ex... |
| - | EpiBiologics | “EpiBiologics” |
| - | EpiBiologics: Protein Degradation Platform Company Closes Over $70 Million | EpiBiologics – a biotechnology company advancing a next-generation antibody-based protein degradation platform and pipeline for membrane and extracellular drug targets – recently announced the company brought the total series A round to $73... |